20170406 Telix Logo.png
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
December 21, 2021 19:49 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with...
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
October 19, 2021 18:12 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
ibn-iw-globe-2.png
InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
January 13, 2021 08:30 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Logo.png
Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
December 17, 2020 11:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Glioblastoma Multiforme Clinical Trial Analysis...
ibn-iw-globe-2.png
InvestorBrandNetwork Announces ‘Want Money Got Money’ Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
December 16, 2020 08:30 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
January 17, 2018 08:00 ET | VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 12, 2017 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
November 10, 2017 08:00 ET | VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
ISR's Brain Cancer (Glioblastoma Multiforme) Report Analyzes Market Opportunity, Product Pipelines
February 19, 2014 09:59 ET | Industry Standard Research
CARY, NC--(Marketwired - Feb 19, 2014) - Industry Standard Research (ISR) today announced the release of a new market research report titled "Brain Cancer (Glioblastoma Multiforme): Disease and...